Nivolumab for previously treated unresectable advanced oesophageal cancer: Appraisal consultation

In DRAFT guidance, nivolumab is not recommended, within its anticipated marketing authorisation, for treating unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma in adults after fluoropyrimidine and platinum-based therapy.

National Institute for Health and Care Excellence